Biogen: Phase 1 Study Of BIIB078 On Amyotrophic Lateral Sclerosis Fails To Meet Secondary Endpoints

WESTON (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Biogen Inc's (BIIB) BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis, did not

Related Keywords

,Ionis Pharmaceuticals Inc ,Biogen Inc ,Biogen ,Hase ,Study ,Iib078 ,Amyotrophic ,Bilateral ,Clerosis ,Nails ,Feet ,Secondary ,Endpoints ,